HD-16: a new quality of life instrument specifically designed for insomnia
ABSTRACT To design a new quality of life (QoL) instrument specifically for insomnia.
Based on severe insomniacs' interviews, we have built a new quality of life scale that has been tested in one group of 240 severe insomniacs, in one group of 422 mild insomniacs and in one group of 391 good sleepers. Ten steps led to the construction of a specific QoL scale.
Five dimensions have been validated as both relevant and independent from each other. Sixteen items out of the 43 initially tested were retained and significantly different within the groups in each dimension. Based on the 16 items selected, we called the scale Hotel Dieu 16 (HD-16). We have therefore verified the score's specificity (correlation score of +0.36) and the reliability of the scale (Cronbach coefficient alpha=0.78).
HD-16 may be used as a focused instrument to better assess an insomniac's quality of life.
- SourceAvailable from: uni-muenchen.de[Show abstract] [Hide abstract]
ABSTRACT: This doctoral project seeks to answer the question about the essence of functioning, disability and health in the lived experience of persons with any kind of primary sleep disorder. Its overall objective is the development of a first version of Core Sets of categories of the International Classification of Functioning, Disability and Health (ICF) in an evidence- and consensus-based process. To this end, four separate studies exploring different perspectives (researcher, clinical, patient, health professional) have been conducted and their results provided the evidence basis for selecting the relevant categories for the ICF Core Sets for Sleep Disorders during an international consensus conference. The doctoral thesis first-authored by the doctoral candidate therefore consists of five separate publications (1 Systematic Review, 2 Patient Studies, 1 Expert Survey, 1 Conference Results) that describe the different steps in the development process.
- [Show abstract] [Hide abstract]
ABSTRACT: Sleep disorders and insomnia at the first raw are unsufficiently diagnosed and treated in primary care. Poor sleep is often not considered as a disease but as a common symptom which does not concern the doctors. However, due to the high number of patients, insomnia has a real impact on economics and on quality of life. The goal of this paper is to review the available litterature on the economical impact of insomnia.Médecine du Sommeil 12/2008; 5(18). DOI:10.1016/S1769-4493(08)70188-2
- [Show abstract] [Hide abstract]
ABSTRACT: Narcolepsy and idiopathic hypersomnia profoundly affect quality of life, education and work. Young patients are very handicapped by unexpected sleep episodes during lessons. Professionals frequently complain about sleepiness at work. Motor discomfort (i.e., cataplectic attacks) surprisingly is less handicapping in narcoleptics than sleepiness but only a few studies clearly assess the problem. Quality of life is also largely impaired in its physical and emotional dimensions. Sleepiness is the major factor explaining a decrease of quality of life and unexpectedly cataplectic attacks have little impact on patients. Another potential problem for these patients is the risk of accidents at work or when driving. Narcoleptic and hypersomniac patients have a higher risk of accidents than apneic or insomniac subjects. But, confounding factors such as duration of driving, number of cataplectic attacks or even objective level of alertness are not always entered in the analytic models mainly because of small samples of patients. Unlike in apneic patients, the effect of treatment on accidental risk has not been studied in narcoleptics or in hypersomniacs. Epidemiological data are needed to improve knowledge concerning these areas. Clinical trials assessing the impact of treatment on driving and work are also urgently needed. Finally, medical treatment does not seem to be completely efficient and physicians should pay more attention to the education, work, life and social environment of their patients.Sleep Medicine Reviews 07/2009; 13(6):421-6. DOI:10.1016/j.smrv.2009.02.001 · 9.14 Impact Factor